Stability of oxaliplatin in infusion bags containing 5% dextrose injection

American Journal of Health-System Pharmacy

Volumn 64, Issue 18, 2007, Pages 1950-1954

  André, Pascal ^a   Cisternino, Salvatore ^a   Roy, Anne Lise ^b   Chiadmi, Fouad ^c   Schlatter, Joël ^c   Agranat, Pascal ^c   Fain, Olivier ^c   Fontan, Jean Eudes ^c  

^a HÔPITAL JEAN VERDIER   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antineoplastic agents; Color; Concentration; Containers; Contamination; Dextrose; Diluents; Hydrogen ion concentration; Injections; Oxaliplatin; Photodecomposition; Polyolefin; Precipitation; Stability; Storage; Temperature

Indexed keywords

GLUCOSE; OXALIPLATIN; POLYOLEFIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ARTICLE; COLOR; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT EXPOSURE; PRIORITY JOURNAL; CHEMISTRY; DRUG PACKAGING; INTRAVENOUS DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; GLUCOSE; INFUSIONS, INTRAVENOUS; ORGANOPLATINUM COMPOUNDS;

EID: 34548780353     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060369     Document Type: Article

References (14)

1. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci. 2002; 59:1914-27.
2. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005; 31:90-105.
3. Food and Drug Administration. Eloxatin (oxaliplatin for injection) package insert. www.fda.gov/cder/foi/label/2004/021492s004lbl.pdf (accessed 2006 Oct 26).
4. Council of Europe. Oxaliplatin monograph. In: The European pharmacopoeia, 5th ed., pt. 2. Aubin, France: European Directorate for the Quality of Medicines and Health Care; 2005:2323-5.
5. Graham MA, Lockwood GF, Greenslade D et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000; 6:1205-18.
6. Summa N, Shiessl W, Puchta R et al. Thermodynamic and kinetic studies on reactions of Pt(II) complexes with biological relevant nucleophiles. Inorg Chem. 2006; 45:2948-59.
7. Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998; 10:595-603.
8. Jerremalm E, Hedeland M, Wallin I et al. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monoxalato complex. Pharm Res. 2004; 21:891-4.
9. Videhult P, Yachnin J, Jerremalm E et al. Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin. Cancer Left. 2002; 180:191-4.
10. Jerremalm E, Videhult P, Alvelius G et al. Alkaline hydrolysis of oxaliplatin - isolation and identification of the oxalato monodentate intermediate. J Pharm Sci. 2002; 91:2116-21.
11. Main P, Heudi O, Cailleux A et al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos. 2000; 28:1379-84.
12. Luo FR, Wyrick SD, Chaney SG. Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol. 1999; 13:159-69.
13. Grolleau F, Gamelin L, Boisdron-Celle M et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001; 85:2293-7.
14. Miller C, Kennington L, Cooney R et al. Oxalate toxicity in renal epithelial cells: characteristics of apoptosis and necrosis. Toxicol Appl Pharmacol. 2000; 162:132-41.